Skip to content

Research at St Andrews

Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London

Research output: Contribution to journalArticle

Author(s)

David M. Livermore, Robert L.R. Hill, Hazel Thomson, André Charlett, Jane F. Turton, Rachel Pike, Bharat C. Patel, Rohini Manuel, Stephen Gillespie, Indran Balakrishnan, Stephen P. Barrett, Nigel Cumberland, Mary Twagira, C-MRAB Study Group

School/Research organisations

Abstract

Carbapenem- and multiply-resistant Acinetobacter baumannii (C-MRAB) are challenging pathogens, often susceptible only to polymyxins and tigecycline. We reviewed clinical outcomes in relation to antibiotic treatment for 166 consecutive patients infected or colonised with these organisms at 18 hospitals around London, UK. Clinical data were obtained along with the isolates, which were typed by pulsed-field gel electrophoresis (PFGE). Outcomes were compared for colonised and infected patients and in relation to treatment, with associations examined by logistic regression. Most subjects (103/166; 62%) were in Intensive Care Units (ICUs) or high dependency units; 84 (50.6%) were judged to be infected and 73 (44.0%) were colonised, with 9 indeterminate. Among the 166 C-MRAB isolates, 141 belonged to OXA-23 clone 1, a European clone II lineage. Survival rates among infected and colonised patients were 68% and 67%, respectively (P > 0.05), indicating little attributable mortality. Univariate and multivariate analyses indicated poorer outcomes among ICU-infected patients and those with pulmonary infection or bacteraemia, whereas trauma patients had significantly better outcomes than the generality. Outcomes varied with hospital, even in multivariate analysis, reflecting either differences in management or case mix. There was little association between outcome and therapy with colistin and/or tigecycline except that, among patients with respiratory infection, 12/15 treated with intravenous colistin alone had poor outcome compared with 1/8 whose therapy include nebulised colistin. This difference was significant (P = 0.003), although the patients receiving nebulised drug were mostly younger, included trauma cases and were at a hospital with good outcomes.
Close

Details

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Volume35
Issue number1
Early online date11 Nov 2009
DOIs
Publication statusPublished - Jan 2010

    Research areas

  • Imipenem, Colistin, Tigecycline, Bacteraemia, Nosocomial pneumonia

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy.

    Research output: Contribution to journalArticle

  2. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  3. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

  4. Molecular bacterial load assay (MBLA) concurs with culture on the NaOH-induced Mycobacterium tuberculosis loss of viability

    Mtafya, B., Sabiiti, W., Sabi, I., John, J., Sichone, E., Ntinginya, N. E. & Gillespie, S. H., 25 Jun 2019, In : Journal of Clinical Microbiology. 57, e01992-18.

    Research output: Contribution to journalArticle

  5. Heat-inactivation renders sputum safe and preserves Mycobacterium tuberculosis RNA for downstream molecular tests

    Sabiiti, W., Azam, K., Esmeraldo, E., Bhatt, N., Rachow, A. & Gillespie, S. H., Mar 2019, In : Journal of Clinical Microbiology. 57, 4, 8 p., e01778-18.

    Research output: Contribution to journalArticle

Related by journal

  1. Emergent and evolving antimicrobial resistance cassettes in community-associated fusidic acid and meticillin-resistant Staphylococcus aureus

    Ellington, M. J., Reuter, S., Harris, S. R., Holden, M. T. G., Cartwright, E. J., Greaves, D., Gerver, S. M., Hope, R., Brown, N. M., Török, M. E., Parkhill, J., Köser, C. U. & Peacock, S. J., May 2015, In : International Journal of Antimicrobial Agents. 45, 5, p. 477-484

    Research output: Contribution to journalArticle

ID: 259232343